Zentalis Pharmaceuticals, Inc.ZNTLEarnings & Financial Report
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted small molecule oncology therapies. Its pipeline targets dysregulated oncogenic pathways, delivering precision treatment options for patients with hard-to-treat cancers across global markets.
ZNTL Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-37.4M
Net Profit
$-35.2M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.50
Zentalis Pharmaceuticals, Inc. Q4 FY2025 Financial Summary
Zentalis Pharmaceuticals, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of $-35.2M (up 25.8% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-35.2M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Zentalis Pharmaceuticals, Inc. Annual Revenue by Year
Zentalis Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
Zentalis Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Zentalis Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-35.2M | N/A |
| Q3 FY2025 | $0 | — | $-26.7M | N/A |
| Q2 FY2025 | $0 | — | $-26.9M | N/A |
| Q1 FY2025 | $0 | — | $-48.3M | N/A |
| Q4 FY2024 | $26.9M | — | $-47.5M | -176.7% |
| Q3 FY2024 | $0 | — | $-40.2M | N/A |
| Q2 FY2024 | $0 | — | $-88.3M | N/A |
| Q1 FY2024 | $40.6M | — | $10.1M | 24.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.6M | $0 | $0 | $26.9M | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $557.5M | $491.7M | $450.7M | $430.3M | $384.0M | $351.7M | $327.3M | $289.0M |
| Liabilities | $98.7M | $109.1M | $96.3M | $93.2M | $88.6M | $77.2M | $74.4M | $72.8M |
| Equity | $458.8M | $382.6M | $354.3M | $337.2M | $295.4M | $274.5M | $252.9M | $216.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-52.0M | $-35.1M | $-44.0M | $-39.7M | $-32.6M | $-34.7M | $-27.0M | $-30.9M |